Skip to content
10-Q

Quarterly Report

BridgeBio Oncology Therapeutics, Inc. BBOT

0001213900-25-070659

← back to feed
Filed
Aug 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$1.03M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$647.1K
Stockholders Equity Q2 2025 · Jun 30, 2025 −$7.27M
Stockholders Equity Q2 2025 · Mar 31, 2025 −$6.15M
Stockholders Equity Q2 2025 · Dec 31, 2024 −$3.73M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$3.37M
Stockholders Equity Q2 2025 · Mar 31, 2024 −$3.22M
Stockholders Equity Q2 2025 · Dec 31, 2023 −$63.57K
Current Liabilities Q2 2025 · Jun 30, 2025 $2.63M
Current Liabilities Q2 2025 · Dec 31, 2024 $187.52K
Total Liabilities Q2 2025 · Jun 30, 2025 $8.15M
Total Liabilities Q2 2025 · Dec 31, 2024 $5.71M
Current Assets Q2 2025 · Jun 30, 2025 $876.78K
Current Assets Q2 2025 · Dec 31, 2024 $1.95M
Total Assets Q2 2025 · Jun 30, 2025 $197.39M
Total Assets Q2 2025 · Dec 31, 2024 $194.42M
Sga Expense Q2 2025 · Jun 30, 2025 $1.12M
Sga Expense Q2 2025 · Jun 30, 2025 $3.54M
Sga Expense Q2 2025 · Jun 30, 2024 $152.34K
Sga Expense Q2 2025 · Jun 30, 2024 $219.04K
Net Income Q2 2025 · Jun 30, 2025 $918.31K
Net Income Q2 2025 · Jun 30, 2025 $430.92K
Net Income Q2 2025 · Mar 31, 2025 −$487.39K
Net Income Q2 2025 · Jun 30, 2024 $2.21M
Net Income Q2 2025 · Jun 30, 2024 $3.31M
Net Income Q2 2025 · Mar 31, 2024 $1.1M
Operating Income Q2 2025 · Jun 30, 2025 −$1.12M
Operating Income Q2 2025 · Jun 30, 2025 −$3.54M
Operating Income Q2 2025 · Jun 30, 2024 −$152.34K
Operating Income Q2 2025 · Jun 30, 2024 −$219.04K